search
Back to results

Fat and Glucose Metabolism in Fed and Fasted State in Patients With Low Skeletal Muscle Mass

Primary Purpose

Spinal Muscular Atrophy, Merosin Deficient Congenital Muscular Dystrophy

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Fasting
Sponsored by
Rigshospitalet, Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Spinal Muscular Atrophy

Eligibility Criteria

1 Year - 80 Years (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients with low skeletal muscle mass

Exclusion Criteria:

  • Competing disorders interfering with interpretation of results
  • Medication that will interfere with results
  • Compliance problems
  • Participation in other clinical trials that will interfere with interpretation of results
  • Pregnancy or breastfeeding

Sites / Locations

  • Copenhagen Neuromuscular Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Fasting

Arm Description

Outcomes

Primary Outcome Measures

Change in fat metabolisms from fed to fasted state
Using indirect calorimetri and stable isotope technique: of [U-13C]-palmitate (0.0026 mg kg-1 min-1, primed by a 0.085 mg kg-1 NaH13CO3 bolus) fat metabolism was measured at fed state and during 24 hours of fasting
Change in carbohydrates metabolisms from fed to fasted state
Using indirect calorimetri and stable isotope technique: of [D2]-glucose (0.0728 mg kg-1 min-1, primed by a 3.203 mg kg-1 D2- glucose bolus) glucose metabolism was measured at fed state and during 24 hours of fasting

Secondary Outcome Measures

Change in insulin, glucagon, epinephrine and norepinephrine and the metabolites palmitate, free fatty acids (FFA), glycerol, glucose, pyruvate, β-hydroxybuturate, acetoacetate from fed to fasted state.
Hormones and metabolites were measured at fed state and during 24 hours of fasting
Change in glucagon from fed to fasted state.
Glucagon was measured at fed state and during 24 hours of fasting
Change in epinephrine from fed to fasted state.
Epinephrine was measured at fed state and during 24 hours of fasting
Change in norepinephrine from fed to fasted state.
Norepinephrine was measured at fed state and during 24 hours of fasting
Change in palmitate from fed to fasted state.
Palmitate was measured at fed state and during 24 hours of fasting
Change in free fatty acids (FFA) from fed to fasted state.
FFA was measured at fed state and during 24 hours of fasting
Change in glycerol from fed to fasted state.
Glycerol was measured at fed state and during 24 hours of fasting
Change in glucose from fed to fasted state.
Glucose was measured at fed state and during 24 hours of fasting
Change in pyruvate from fed to fasted state.
Pyruvate was measured at fed state and during 24 hours of fasting
Change in β-hydroxybuturate from fed to fasted state.
β-hydroxybuturatewas measured at fed state and during 24 hours of fasting
Change in acetoacetate from fed to fasted state.
Acetoacetate was measured at fed state and during 24 hours of fasting

Full Information

First Posted
May 21, 2019
Last Updated
May 29, 2019
Sponsor
Rigshospitalet, Denmark
search

1. Study Identification

Unique Protocol Identification Number
NCT03970135
Brief Title
Fat and Glucose Metabolism in Fed and Fasted State in Patients With Low Skeletal Muscle Mass
Official Title
Fedt og Sukkerstofskiftet Under Faste Hos Patienter Med Lav Muskelmasse.
Study Type
Interventional

2. Study Status

Record Verification Date
May 2019
Overall Recruitment Status
Completed
Study Start Date
May 29, 2017 (Actual)
Primary Completion Date
November 30, 2017 (Actual)
Study Completion Date
November 30, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rigshospitalet, Denmark

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In a study from 2003 the investigators showed that adult patients with very low skeletal muscle mass (spinal muscular atrophy (SMA) type II, Duchenne muscular dystrophy, congenital muscular dystrophy) are prone to develop hypoglycemia during prolonged fasting. Since then case reports have described the same phenomenon with hypoglycemia and metabolic crises in children with low skeletal muscle mass provoked by infection, fasting and surgery. Pathophysiological mechanisms of metabolism have never been investigated in adults or children with SMA II. Thus the investigators studied fat and glucose metabolism during prolonged fasting in patients with SMA II and LAMA 2 and compared results to those found in healthy controls.
Detailed Description
Design. This is a prospective case-control study investigating fat and glucose metabolism in patients with low muscle mass during prolonged fasting, comparing results to those found in healthy controls. Setting. All children were admitted to the Department of Pediatrics and Adolescents medicine, Rigshospitalet, and all adult subjects were admitted to the Department of Neurology, Rigshospitalet at 4 pm for a 24-hour fasting period. Protocol. The protocol consisted of two visits. A pre-experimental visit and a study visit. Pre-experimental visit. Total muscle mass presented as lean body mass (LBM) was measured by DEXA scan. Furthermore, pre-experimental preparations included that all subjects were instructed to follow national nutritional recommendations with a healthy diet consisting of less than 30% fat, low fat protein, long chain carbohydrates and minimize sugar intake three days before the study. Study visit. Patients were admitted to the hospital at 16:00 hours for IV catheter placement and a standardized evening meal at 17:00. Two venous catheters were inserted, one in the cubital vein (for stable-isotope infusion) and one in the distal cephalic vein (for blood sampling). A heating pad, covering the hand and distal forearm, ensured shunting of arterial blood to the veins in order to obtain arterialized blood. A primed, constant rate infusion of [U-13C]-palmitate (0.0026 mg kg-1 min-1, primed by a 0.085 mg kg-1 NaH13CO3 bolus) and [D2]-glucose (0.0728 mg kg-1 min-1, primed by a 3.203 mg kg-1 D2- glucose bolus) was delivered by a Gemini PC2 pump (IMED, San Diego, CA). Preparation of tracers and tracer calculations were performed as described. Blood and air samples were collected just before start of infusion of the stable isotopes, and again after 2, 10, 14, 16, 18, 20, 22 and 24 hours of fasting (figure 1). Gas exchange measurements (indirect calorimetry) were performed with a metabolic cart (Cosmed Quark b2; Cosmed Srl., Milan, Italy). At the same time-points, expired air was collected in a 15 L Douglas bag (Hans Rudolph, Kansas City, MO, USA) and 10 mL samples were transferred to vacuum tubes (Vacutainer, BD, Franklin Lakes, NJ, USA) for 13CO2 analysis. The blood glucose levels were monitored continuously at all blood sampling times and every third hour during the night in the patients. If the subjects developed symptoms of hypoglycaemia (fatigue, dizziness, nausea) the blood sugar was measured immediately. The fasting period lasted 24 hours or until signs of hypoglycemia as mentioned above or blood glucose below 3.0 mmol/L. Patients received an IV bolus of 10% glucose according to weight if signs of hypoglycemia occurred. Analyses of blood samples and expired 13CO2. Venous blood was transferred to cooled tubes with EDTA (Ethylenediaminetetraacetic acid) (0.33M, 10μL mL-1) and spun at 4,000 rpm for 10 minutes. Plasma was distributed to Eppendorf tubes and immediately frozen on dry ice and stored at -80°C until analysis. Plasma insulin and glucagon analyses were performed at the Department of Clinical Biochemistry at Rigshospitalet, Copenhagen, Denmark (Cobas 8000, Roche, Rotkreuz Switzerland). Plasma free fatty acids and catecholamines were analyzed by spectrophotometry (Multiskan GO, Thermo Scientific, SkanIt™ Software, Thermo Fisher Scientific Inc., USA). Plasma palmitate, β-hydroxybuturate, acetoacetate, pyruvate, glycerol and amino acids as well as 13CO2-breath enrichment were analyzed by gas chromatography isotope ratio-mass spectrometry (Thermo Finnigan MAT GmbH, Bremen, Germany). Isotope tracer enrichments were determined using gas chromatography-mass spectrometry (Thermo Finnigan MAT GmbH, Bremen, Germany). Glucose and lactate were analyzed on (ABL 700) immediately as the blood was drawn. Shofield equation was used to calculate expected basal metabolic rate for the children: Males 10-17 years: (17.7 x weight+657+105) and females 10-17 years: (13,4 x weight+692+112) and the results were compared with the resting metabolic rate (RMR) measured by indirect calorimetric, as described above, at the end of the study, were patients had been resting and fasting for more than 8 hours.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Muscular Atrophy, Merosin Deficient Congenital Muscular Dystrophy

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
13 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Fasting
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
Fasting
Intervention Description
Fasting for 24 hours or until hypoglycemia (blood glucose < 3mmol/L) or symptoms of hypoglycemia
Primary Outcome Measure Information:
Title
Change in fat metabolisms from fed to fasted state
Description
Using indirect calorimetri and stable isotope technique: of [U-13C]-palmitate (0.0026 mg kg-1 min-1, primed by a 0.085 mg kg-1 NaH13CO3 bolus) fat metabolism was measured at fed state and during 24 hours of fasting
Time Frame
24 hours
Title
Change in carbohydrates metabolisms from fed to fasted state
Description
Using indirect calorimetri and stable isotope technique: of [D2]-glucose (0.0728 mg kg-1 min-1, primed by a 3.203 mg kg-1 D2- glucose bolus) glucose metabolism was measured at fed state and during 24 hours of fasting
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Change in insulin, glucagon, epinephrine and norepinephrine and the metabolites palmitate, free fatty acids (FFA), glycerol, glucose, pyruvate, β-hydroxybuturate, acetoacetate from fed to fasted state.
Description
Hormones and metabolites were measured at fed state and during 24 hours of fasting
Time Frame
24 hours
Title
Change in glucagon from fed to fasted state.
Description
Glucagon was measured at fed state and during 24 hours of fasting
Time Frame
24 hours
Title
Change in epinephrine from fed to fasted state.
Description
Epinephrine was measured at fed state and during 24 hours of fasting
Time Frame
24 hours
Title
Change in norepinephrine from fed to fasted state.
Description
Norepinephrine was measured at fed state and during 24 hours of fasting
Time Frame
24 hours
Title
Change in palmitate from fed to fasted state.
Description
Palmitate was measured at fed state and during 24 hours of fasting
Time Frame
24 hours
Title
Change in free fatty acids (FFA) from fed to fasted state.
Description
FFA was measured at fed state and during 24 hours of fasting
Time Frame
24 hours
Title
Change in glycerol from fed to fasted state.
Description
Glycerol was measured at fed state and during 24 hours of fasting
Time Frame
24 hours
Title
Change in glucose from fed to fasted state.
Description
Glucose was measured at fed state and during 24 hours of fasting
Time Frame
24 hours
Title
Change in pyruvate from fed to fasted state.
Description
Pyruvate was measured at fed state and during 24 hours of fasting
Time Frame
24 hours
Title
Change in β-hydroxybuturate from fed to fasted state.
Description
β-hydroxybuturatewas measured at fed state and during 24 hours of fasting
Time Frame
24 hours
Title
Change in acetoacetate from fed to fasted state.
Description
Acetoacetate was measured at fed state and during 24 hours of fasting
Time Frame
24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients with low skeletal muscle mass Exclusion Criteria: Competing disorders interfering with interpretation of results Medication that will interfere with results Compliance problems Participation in other clinical trials that will interfere with interpretation of results Pregnancy or breastfeeding
Facility Information:
Facility Name
Copenhagen Neuromuscular Center
City
Copenhagen
ZIP/Postal Code
2200
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Fat and Glucose Metabolism in Fed and Fasted State in Patients With Low Skeletal Muscle Mass

We'll reach out to this number within 24 hrs